4.5 Review

Designing CD8+T cell vaccines: it's not rocket science (yet)

Journal

CURRENT OPINION IN IMMUNOLOGY
Volume 22, Issue 3, Pages 402-410

Publisher

CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2010.04.002

Keywords

-

Categories

Funding

  1. Intramural NIH HHS [Z01 AI000542-20] Funding Source: Medline
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000658, ZIAAI000542] Funding Source: NIH RePORTER

Ask authors/readers for more resources

CD8+ T cells play important roles in clearing viral infections and eradicating tumors. Designing vaccines that elicit effective CD8+ T cell responses requires a thorough knowledge of the pathways of antigen presentation in vivo. Here, I review recent progress in understanding the activation of naive CD8+ T cells in vivo, with particular emphasis on cross-priming, the presentation of protein antigens acquired by dendritic cells from their environment. With the rapid advances in this area of research, the dawn of rational vaccine design is at hand.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available